Literature DB >> 26825642

Age-Dependent Human Hepatic Carboxylesterase 1 (CES1) and Carboxylesterase 2 (CES2) Postnatal Ontogeny.

Ronald N Hines1, Pippa M Simpson2, D Gail McCarver2.   

Abstract

Human hepatic carboxylesterase 1 and 2 (CES1 and CES2) are important for the disposition of ester- and amide-bond-containing pharmaceuticals and environmental chemicals. CES1 and CES2 ontogeny has not been well characterized, causing difficulty in addressing concerns regarding juvenile sensitivity to adverse outcomes associated with exposure to certain substrates. To characterize postnatal human hepatic CES1 and CES2 expression, microsomal and cytosolic fractions were prepared using liver samples from subjects without liver disease (N = 165, aged 1 day to 18 years). Proteins were fractionated, detected, and quantitated by Western blotting. Median microsomal CES1 was lower among samples from subjects younger than 3 weeks (n = 36) compared with the rest of the population (n = 126; 6.27 vs. 17.5 pmol/mg microsomal protein, respectively; P < 0.001; Kruskal-Wallis test). Median cytosolic CES1 expression was lowest among samples from individuals between birth and 3 weeks of age (n = 36), markedly greater among those aged 3 weeks to 6 years (n = 90), and modestly greater still among those older than 6 years (n = 36; median values = 4.7, 15.8, and 16.6 pmol/mg cytosolic protein, respectively; P values < 0.001 and 0.05, respectively; Kruskal-Wallis test). Median microsomal CES2 expression increased across the same three age groups with median values of 1.8, 2.9, and 4.2 pmol/mg microsomal protein, respectively (P < 0.001, both). For cytosolic CES2, only the youngest age group differed from the two older groups (P < 0.001; median values = 1.29, 1.93, 2.0, respectively). These data suggest that infants younger than 3 weeks of age would exhibit significantly lower CES1- and CES2-dependent metabolic clearance compared with older individuals.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26825642     DOI: 10.1124/dmd.115.068957

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  16 in total

1.  Age-Related Changes in Expression and Activity of Human Hepatic Mitochondrial Glutathione Transferase Zeta1.

Authors:  Guo Zhong; Margaret O James; Marci G Smeltz; Stephan C Jahn; Taimour Langaee; Pippa Simpson; Peter W Stacpoole
Journal:  Drug Metab Dispos       Date:  2018-05-31       Impact factor: 3.922

Review 2.  Carboxylesterase 1 and Precision Pharmacotherapy: Pharmacogenetics and Nongenetic Regulators.

Authors:  Lucy Her; Hao-Jie Zhu
Journal:  Drug Metab Dispos       Date:  2019-12-23       Impact factor: 3.922

Review 3.  Genetics of the patent ductus arteriosus (PDA) and pharmacogenetics of PDA treatment.

Authors:  Tamorah R Lewis; Elaine L Shelton; Sara L Van Driest; Prince J Kannankeril; Jeff Reese
Journal:  Semin Fetal Neonatal Med       Date:  2018-02-24       Impact factor: 3.926

4.  Physiologically-Based Pharmacokinetic/Pharmacodynamic Model of MBQ-167 to Predict Tumor Growth Inhibition in Mice.

Authors:  Javier Reig-López; María Del Mar Maldonado; Matilde Merino-Sanjuan; Ailed M Cruz-Collazo; Jean F Ruiz-Calderón; Victor Mangas-Sanjuán; Suranganie Dharmawardhane; Jorge Duconge
Journal:  Pharmaceutics       Date:  2020-10-15       Impact factor: 6.321

5.  A Time-Embedding Network Models the Ontogeny of 23 Hepatic Drug Metabolizing Enzymes.

Authors:  Matthew K Matlock; Abhik Tambe; Jack Elliott-Higgins; Ronald N Hines; Grover P Miller; S Joshua Swamidass
Journal:  Chem Res Toxicol       Date:  2019-07-29       Impact factor: 3.739

6.  A framework and case studies for evaluation of enzyme ontogeny in children's health risk evaluation.

Authors:  Gary Ginsberg; Suryanarayana V Vulimiri; Yu-Sheng Lin; Jayaram Kancherla; Brenda Foos; Babasaheb Sonawane
Journal:  J Toxicol Environ Health A       Date:  2017-09-11

7.  Association of Oseltamivir Activation with Gender and Carboxylesterase 1 Genetic Polymorphisms.

Authors:  Jian Shi; Xinwen Wang; Rachel F Eyler; Yan Liang; Li Liu; Bruce A Mueller; Hao-Jie Zhu
Journal:  Basic Clin Pharmacol Toxicol       Date:  2016-07-21       Impact factor: 4.080

8.  Age-Dependent Absolute Abundance of Hepatic Carboxylesterases (CES1 and CES2) by LC-MS/MS Proteomics: Application to PBPK Modeling of Oseltamivir In Vivo Pharmacokinetics in Infants.

Authors:  Mikael Boberg; Marc Vrana; Aanchal Mehrotra; Robin E Pearce; Andrea Gaedigk; Deepak Kumar Bhatt; J Steven Leeder; Bhagwat Prasad
Journal:  Drug Metab Dispos       Date:  2016-11-28       Impact factor: 3.922

9.  In vitro age-related differences in rats to organophosphates.

Authors:  Edward C Meek; Russell L Carr; Janice E Chambers
Journal:  Toxicol In Vitro       Date:  2021-01-23       Impact factor: 3.500

Review 10.  Human carboxylesterases and fluorescent probes to image their activity in live cells.

Authors:  Anchal Singh; Mingze Gao; Michael W Beck
Journal:  RSC Med Chem       Date:  2021-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.